{"count": 9, "results": [{"_id": "33183458", "pmid": 33183458, "title": "Effects of Liposomal Simvastatin Nanoparticles on Vascular Endothelial Function and Arterial Smooth Muscle Cell Apoptosis in Rats with Arteriosclerotic Occlusive Disease of Lower Limb via P38 Mitogen-Activated Protein Kinase Nuclear Factor Kappa-B Pathway.", "journal": "J Nanosci Nanotechnol", "authors": ["Wu J", "Liao S", "Hu Q", "Wu S", "Qiu S", "Cheng G", "Li X", "Lu W"], "date": "2021-02-01T00:00:00Z", "doi": "10.1166/jnn.2021.18632", "meta_date_publication": "2021 Feb 1", "meta_volume": "21", "meta_issue": "2", "meta_pages": "1169-1175", "score": 50255.56, "text_hl": "This article prepared a @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@-NLCs for the treatment of @<m>DISEASE_Arterial_Occlusive_Diseases</m> @DISEASE_MESH:D001157 @@@arteriosclerotic occlusive disease@@@ of lower limbs. ", "citations": {"NLM": "Wu J, Liao S, Hu Q, Wu S, Qiu S, Cheng G, Li X, Lu W. Effects of Liposomal Simvastatin Nanoparticles on Vascular Endothelial Function and Arterial Smooth Muscle Cell Apoptosis in Rats with Arteriosclerotic Occlusive Disease of Lower Limb via P38 Mitogen-Activated Protein Kinase Nuclear Factor Kappa-B Pathway. J Nanosci Nanotechnol. 2021 Feb 1;21(2):1169-1175. PMID: 33183458", "BibTeX": "@article{33183458, title={Effects of Liposomal Simvastatin Nanoparticles on Vascular Endothelial Function and Arterial Smooth Muscle Cell Apoptosis in Rats with Arteriosclerotic Occlusive Disease of Lower Limb via P38 Mitogen-Activated Protein Kinase Nuclear Factor Kappa-B Pathway.}, author={Wu J and Liao S and Hu Q and Wu S and Qiu S and Cheng G and Li X and Lu W}, journal={J Nanosci Nanotechnol}, volume={21}, number={2}, pages={1169-1175}}"}}, {"_id": "11018199", "pmid": 11018199, "title": "Effect of simvastatin on restenosis after percutaneous transluminal angioplasty of femoropopliteal arterial obstruction.", "journal": "Am J Cardiol", "authors": ["Hagenaars T", "Gussenhoven EJ", "van Sambeek MR", "Jukema JW", "Kranendonk SE", "Bom N"], "date": "2000-10-01T00:00:00Z", "doi": "10.1016/s0002-9149(00)01079-1", "meta_date_publication": "2000 Oct 1", "meta_volume": "86", "meta_issue": "7", "meta_pages": "774-6, A6", "score": 50070.703, "text_hl": "Effect of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ on @DISEASE_Coronary_Restenosis @DISEASE_MESH:D023903 @@@restenosis@@@ after percutaneous transluminal angioplasty of @<m>DISEASE_Arterial_Occlusive_Diseases</m> @DISEASE_MESH:D001157 @@@femoropopliteal arterial obstruction@@@.", "citations": {"NLM": "Hagenaars T, Gussenhoven EJ, van Sambeek MR, Jukema JW, Kranendonk SE, Bom N. Effect of simvastatin on restenosis after percutaneous transluminal angioplasty of femoropopliteal arterial obstruction. Am J Cardiol. 2000 Oct 1;86(7):774-6, A6. PMID: 11018199", "BibTeX": "@article{11018199, title={Effect of simvastatin on restenosis after percutaneous transluminal angioplasty of femoropopliteal arterial obstruction.}, author={Hagenaars T and Gussenhoven EJ and van Sambeek MR and Jukema JW and Kranendonk SE and Bom N}, journal={Am J Cardiol}, volume={86}, number={7}, pages={774-6, A6}}"}}, {"_id": "11676957", "pmid": 11676957, "title": "Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease.", "journal": "Am J Cardiol", "authors": ["Christenson JT"], "date": "2001-10-15T00:00:00Z", "doi": "10.1016/s0002-9149(01)01901-4", "meta_date_publication": "2001 Oct 15", "meta_volume": "88", "meta_issue": "8", "meta_pages": "896-9, A8", "score": 50064.855, "text_hl": "Preoperative @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@ control with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ protects coronary artery bypass grafts from @<m>DISEASE_Arterial_Occlusive_Diseases</m> @DISEASE_MESH:D001157 @@@obstructive graft disease@@@.", "citations": {"NLM": "Christenson JT. Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease. Am J Cardiol. 2001 Oct 15;88(8):896-9, A8. PMID: 11676957", "BibTeX": "@article{11676957, title={Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease.}, author={Christenson JT}, journal={Am J Cardiol}, volume={88}, number={8}, pages={896-9, A8}}"}}, {"_id": "17098764", "pmid": 17098764, "title": "Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.", "journal": "BMJ", "authors": ["Heart Protection Study Collaborative", "Mihaylova B", "Briggs A", "Armitage J", "Parish S", "Gray A", "Collins R"], "date": "2006-12-02T00:00:00Z", "doi": "10.1136/bmj.38993.731725.BE", "meta_date_publication": "2006 Dec 2", "meta_volume": "333", "meta_issue": "7579", "meta_pages": "1145", "score": 50049.516, "text_hl": "Lifetime cost effectiveness of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ in a range of risk groups and age groups derived from a randomised trial of 20,536 people.", "citations": {"NLM": "Heart Protection Study Collaborative, Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ. 2006 Dec 2;333(7579):1145. PMID: 17098764", "BibTeX": "@article{17098764, title={Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.}, author={Heart Protection Study Collaborative and Mihaylova B and Briggs A and Armitage J and Parish S and Gray A and Collins R}, journal={BMJ}, volume={333}, number={7579}, pages={1145}}"}}, {"_id": "12814710", "pmid": 12814710, "title": "MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.", "journal": "Lancet", "authors": ["Collins R", "Armitage J", "Parish S", "Sleigh P", "Peto R", "Heart Protection Study Collaborative Group"], "date": "2003-06-14T00:00:00Z", "doi": "10.1016/s0140-6736(03)13636-7", "meta_date_publication": "2003 Jun 14", "meta_volume": "361", "meta_issue": "9374", "meta_pages": "2005-16", "score": 50047.8, "text_hl": "METHODS: 5963 UK adults (aged 40-80 years) known to have @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@, and an additional 14573 with @<m>DISEASE_Arterial_Occlusive_Diseases</m> @DISEASE_MESH:D001157 @@@occlusive arterial disease@@@ (but no diagnosed @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@), were randomly allocated to receive 40 mg @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ daily or matching placebo. ", "citations": {"NLM": "Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 Jun 14;361(9374):2005-16. PMID: 12814710", "BibTeX": "@article{12814710, title={MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.}, author={Collins R and Armitage J and Parish S and Sleigh P and Peto R and Heart Protection Study Collaborative Group}, journal={Lancet}, volume={361}, number={9374}, pages={2005-16}}"}}, {"_id": "12440352", "pmid": 12440352, "title": "[Clinical study of the month. The MRC/BHF Heart Protection Study].", "journal": "Rev Med Liege", "authors": ["Kulbertus H", "Scheen AJ"], "date": "2002-09-01T00:00:00Z", "meta_date_publication": "2002 Sep", "meta_volume": "57", "meta_issue": "9", "meta_pages": "613-6", "score": 50044.773, "text_hl": "20,536 adults (15,454 @SPECIES_9606 @@@men@@@ and 5,082 @SPECIES_9606 @@@women@@@, aged 40-80 years) with @DISEASE_Coronary_Disease @DISEASE_MESH:D003327 @@@coronary heart disease@@@, other @<m>DISEASE_Arterial_Occlusive_Diseases</m> @DISEASE_MESH:D001157 @@@occlusive arterial disease@@@ or @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes mellitus@@@ were randomly allocated to receive 40 mg @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ daily or matching placebo. ", "citations": {"NLM": "Kulbertus H, Scheen AJ. [Clinical study of the month. The MRC/BHF Heart Protection Study]. Rev Med Liege. 2002 Sep;57(9):613-6. PMID: 12440352", "BibTeX": "@article{12440352, title={[Clinical study of the month. The MRC/BHF Heart Protection Study].}, author={Kulbertus H and Scheen AJ}, journal={Rev Med Liege}, volume={57}, number={9}, pages={613-6}}"}}, {"_id": "12114036", "pmid": 12114036, "title": "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.", "journal": "Lancet", "authors": ["Heart Protection Study Collaborative Group"], "date": "2002-07-06T00:00:00Z", "doi": "10.1016/S0140-6736(02)09327-3", "meta_date_publication": "2002 Jul 6", "meta_volume": "360", "meta_issue": "9326", "meta_pages": "7-22", "score": 50041.05, "text_hl": "METHODS: 20,536 UK adults (aged 40-80 years) with @DISEASE_Coronary_Disease @DISEASE_MESH:D003327 @@@coronary disease@@@, other @<m>DISEASE_Arterial_Occlusive_Diseases</m> @DISEASE_MESH:D001157 @@@occlusive@@@ @DISEASE_Cerebral_Arterial_Diseases @DISEASE_MESH:D002539 @@@arterial disease@@@, or @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ were randomly allocated to receive 40 mg @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ daily (average compliance: 85%) or matching placebo (average non-study statin use: 17%). ", "citations": {"NLM": "Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7-22. PMID: 12114036", "BibTeX": "@article{12114036, title={MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.}, author={Heart Protection Study Collaborative Group}, journal={Lancet}, volume={360}, number={9326}, pages={7-22}}"}}, {"_id": "15016485", "pmid": 15016485, "title": "Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.", "journal": "Lancet", "authors": ["Collins R", "Armitage J", "Parish S", "Sleight P", "Peto R", "Heart Protection Study Collaborative Group"], "date": "2004-03-06T00:00:00Z", "doi": "10.1016/S0140-6736(04)15690-0", "meta_date_publication": "2004 Mar 6", "meta_volume": "363", "meta_issue": "9411", "meta_pages": "757-67", "score": 50040.01, "text_hl": "METHODS: 3280 adults with @DISEASE_Cerebrovascular_Disorders @DISEASE_MESH:D002561 @@@cerebrovascular disease@@@, and an additional 17256 with other @<m>DISEASE_Arterial_Occlusive_Diseases</m> @DISEASE_MESH:D001157 @@@occlusive arterial disease@@@ or @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@, were randomly allocated 40 mg @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ daily or matching placebo. ", "citations": {"NLM": "Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004 Mar 6;363(9411):757-67. PMID: 15016485", "BibTeX": "@article{15016485, title={Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.}, author={Collins R and Armitage J and Parish S and Sleight P and Peto R and Heart Protection Study Collaborative Group}, journal={Lancet}, volume={363}, number={9411}, pages={757-67}}"}}, {"_id": "23444397", "pmid": 23444397, "pmcid": "PMC3640201", "title": "HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment", "journal": "Eur Heart J", "authors": ["HPS2-THRIVE Collaborative Group"], "date": "2013-05-01T00:00:00Z", "doi": "10.1093/eurheartj/eht055", "meta_date_publication": "2013 May", "meta_volume": "34", "meta_issue": "17", "meta_pages": "1279-91", "score": 50038.16, "text_hl": "Prior to randomization, 42 424 @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Arterial_Occlusive_Diseases</m> @DISEASE_MESH:D001157 @@@occlusive arterial disease@@@ were given @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ 40 mg plus, if required, @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ 10 mg daily to standardize their low-density lipoprotein (LDL)-lowering therapy. ", "citations": {"NLM": "HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J. 2013 May;34(17):1279-91. PMID: 23444397", "BibTeX": "@article{23444397, title={HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment}, author={HPS2-THRIVE Collaborative Group}, journal={Eur Heart J}, volume={34}, number={17}, pages={1279-91}}"}}]}